BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 35202405)

  • 1. Stage-differentiated ensemble modeling of DNA methylation landscapes uncovers salient biomarkers and prognostic signatures in colorectal cancer progression.
    Muthamilselvan S; Raghavendran A; Palaniappan A
    PLoS One; 2022; 17(2):e0249151. PubMed ID: 35202405
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
    McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
    BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Walking pathways with positive feedback loops reveal DNA methylation biomarkers of colorectal cancer.
    Kel A; Boyarskikh U; Stegmaier P; Leskov LS; Sokolov AV; Yevshin I; Mandrik N; Stelmashenko D; Koschmann J; Kel-Margoulis O; Krull M; Martínez-Cardús A; Moran S; Esteller M; Kolpakov F; Filipenko M; Wingender E
    BMC Bioinformatics; 2019 Apr; 20(Suppl 4):119. PubMed ID: 30999858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
    Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
    Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?
    Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH
    Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unmasking early colorectal cancer clues: in silico and in vitro investigation of downregulated IGF2, SOCS1, MLH1, and CACNA1G in SSA polyps.
    Mirbahari SN; Fatemi N; Savabkar S; Chaleshi V; Zali N; Taleghani MY; Mirzaei E; Rejali L; Moghadam PK; Mojarad EN
    Mol Biol Rep; 2024 Jun; 51(1):764. PubMed ID: 38874740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrative Analysis of DNA Methylation and Gene Expression Profiles Identifies Colorectal Cancer-Related Diagnostic Biomarkers.
    Xu M; Yuan L; Wang Y; Chen S; Zhang L; Zhang X
    Pathol Oncol Res; 2021; 27():1609784. PubMed ID: 34366718
    [No Abstract]   [Full Text] [Related]  

  • 8. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
    Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
    Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential DNA methylation changes are associated with DNMT3B overexpression in colorectal neoplastic progression.
    Ibrahim AE; Arends MJ; Silva AL; Wyllie AH; Greger L; Ito Y; Vowler SL; Huang TH; Tavaré S; Murrell A; Brenton JD
    Gut; 2011 Apr; 60(4):499-508. PubMed ID: 21068132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
    Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
    Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic variants of methyl metabolizing enzymes and epigenetic regulators: associations with promoter CpG island hypermethylation in colorectal cancer.
    de Vogel S; Wouters KA; Gottschalk RW; van Schooten FJ; de Goeij AF; de Bruïne AP; Goldbohm RA; van den Brandt PA; Weijenberg MP; van Engeland M
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3086-96. PubMed ID: 19843671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea.
    Joe S; Kim J; Lee JY; Jeon J; Byeon I; Han SW; Ryoo SB; Park KJ; Song SH; Cho S; Shim H; Bao Khanh Chu H; Kang J; Lee HS; Kim D; Kim YJ; Kim TY; Kim SY
    BMB Rep; 2023 Oct; 56(10):563-568. PubMed ID: 37574809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
    Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
    Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and validation of 3-CpG methylation prognostic signature based on different survival indicators for colorectal cancer.
    Huang H; Zhang L; Fu J; Tian T; Liu X; Liu Y; Sun H; Li D; Zhu L; Xu J; Zheng T; Jia C; Zhao Y
    Mol Carcinog; 2021 Jun; 60(6):403-412. PubMed ID: 33826760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel DNA methylation panel accurately detects colorectal cancer independently of molecular pathway.
    Freitas M; Ferreira F; Carvalho S; Silva F; Lopes P; Antunes L; Salta S; Diniz F; Santos LL; Videira JF; Henrique R; Jerónimo C
    J Transl Med; 2018 Feb; 16(1):45. PubMed ID: 29486770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic profiling and mRNA expression reveal candidate genes as biomarkers for colorectal cancer.
    Zhang H; Dong S; Feng J
    J Cell Biochem; 2019 Jun; 120(6):10767-10776. PubMed ID: 30672027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel methylation gene panel in adjacent normal tissues predicts poor prognosis of colorectal cancer in Taiwan.
    Hsu CH; Hsiao CW; Sun CA; Wu WC; Yang T; Hu JM; Huang CH; Liao YC; Chen CY; Lin FH; Chou YC
    World J Gastroenterol; 2020 Jan; 26(2):154-167. PubMed ID: 31988582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide DNA methylation analysis of colorectal adenomas with and without recurrence reveals an association between cytosine-phosphate-guanine methylation and histological subtypes.
    Fiedler D; Hirsch D; El Hajj N; Yang HH; Hu Y; Sticht C; Nanda I; Belle S; Rueschoff J; Lee MP; Ried T; Haaf T; Gaiser T
    Genes Chromosomes Cancer; 2019 Nov; 58(11):783-797. PubMed ID: 31334584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
    Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
    Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
    Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
    Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.